Author Information
Ulrich Brinkmann is a distinguished researcher affiliated with Roche Pharma Research & Early Development, specifically within the Large Molecule Research division at the Roche Innovation Center Munich, located in Penzberg, Germany. His work is primarily focused on the development and innovation of pharmaceutical solutions, particularly in the area of bi- and multispecific antibodies, as well as the role of microRNAs in cancer research. His contributions have been pivotal in advancing our understanding of complex biological mechanisms and therapeutic interventions.Research Contributions
Ulrich Brinkmann has made significant contributions to the field of biopharmaceutical research, with a particular emphasis on antibody engineering and cancer therapeutics. His recent work includes the development of Prodrug-Activating Chain Exchange (PACE) technology, which enhances the functionality of targeted prodrug derivatives into bi- or multispecific antibodies. He has also delved into the therapeutic potential of circular RNAs in esophageal squamous cell carcinoma, and the role of microRNAs in various types of cancer, including gastric carcinoma, melanoma, and colorectal cancer. His research is characterized by a strong focus on innovative approaches to cancer treatment, leveraging advanced molecular biology techniques.Aliases
Ulrich Brinkmann is known by several aliases in academic publications, including U Brinkmann, U. Brinkmann, and U. S. Brinkmann. These variations are frequently used in the literature to refer to his extensive body of work across different studies and collaborations.Publication and Citation Metrics
| Metric |
Value |
| Citation Count |
12,835 |
| H-index |
51 |
| Paper Count |
192 |
